1
Q
glucocorticoids
A
- moa: lymphocytic
- first line for autoimmune and inflammatory diseases
- se: cushings, hyperglycemia, hpn, avascular necrosis, etc
2
Q
calcineurin inhibitors
A
- cyclosporin and tacrolimus
- moa: inhibits calcineurin = immunosuppression and less inflammation
- indication: organ dysfunction, gvhd, autoimmune
- se: nephrotoxic, seizures, hirsutism, liver dysfunction
3
Q
mtor inhibitors
A
- “limus”
- moa: inhibition of mtor = inhibit cell growth, proliferation, and angiogenesis
- se: myelosuppression and hepatotoxicity
4
Q
mycophenolate mofetil
A
- moa: inhibits t and b lymphocyte responses
- indication: organ transplant, gvhd, autoimmune
- se: gi disturbance, neutropenia, hpn
5
Q
sulfasalazine and mesalazine
A
- moa: suppress t cell response, b cell proliferation, inhibit cytokine release
- indication: ibd, ra, ankylosing spondylitis
6
Q
azathioprine and mercaptopurine
A
- moa: antimetabolite
- indication: renal transplant, autoimmune
- se: myelosuppression and leukopenia
7
Q
cyclophosphamide
A
- moa: alkylating agent
- indication: chemo, autoimmune
- se: pancytopenia
8
Q
hydroxychloroquine
A
- moa: decreased t cell activation
- indication: antimalarial, autoimmune disorders
- se: optic neuritis, blindness, qt prolongation
9
Q
immunomodulatory imide drugs
A
- “domide”
- moa: inhibits tnfa
- indication: mm, erythema nodosum leprosum
- autoimmune diseases
- se: teratogenic, peripheral neuropathy, thrombotic events
10
Q
protease inhibitors
A
- “zomib”
- inhibits proteasome
- indication: mm, mantle cell lymphoma, hyperimmune syndromes
11
Q
tyrosine kinase inhibitors
A
- moa: block phosphorylation and downstream signaling pathways
- indications: read
12
Q
biologics
A
monoclonal antibodies = mab interferons = ifn jak inhibitors = tinib car t cells = leucel immune checkpoint ihibitors = pembrolizumab and nivolumab
